Boothbay Fund Management’s Strongbridge Biopharma plc. SBBP Stock Holding History

Boothbay Fund Management’s Portfolio SBBP Stock Details SBBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-143,577	Closed	-$426K	–	2381
2021 Q2	$426K	Buy	143,577 +12,629	+10%	+$33.3K	0.01%	1090
2021 Q1	$361K	Sell	130,948 -144,389	-52%	-$436K	0.01%	1111
2020 Q4	$669K	Sell	275,337 -104,061	-27%	-$251K	0.02%	641
2020 Q3	$797K	Sell	379,398 -3,002	-0.8%	-$10.1K	0.05%	499
2020 Q2	$1.45M	Sell	382,400 -5,909	-2%	-$17.7K	0.1%	276
2020 Q1	$734K	Buy	+388,309	New	+$1.01M	0.06%	370
2019 Q3	–	Sell	-120,000	Closed	-$376K	–	965
2019 Q2	$376K	Buy	120,000 +20,000	+20%	+$73.4K	0.03%	487
2019 Q1	$498K	Buy	100,000 +48,000	+92%	+$236K	0.05%	381
2018 Q4	$233K	Buy	+52,000	New	+$254K	0.03%	452

Other funds holding SBBP

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Boothbay Fund Management's SBBP Position: Q3 2021 in Review

Boothbay Fund Management sold out of Strongbridge Biopharma plc. (SBBP) in Q3 2021, closing a stake of 143,577 shares — an estimated $426K sold.

Boothbay Fund Management first reported a position in SBBP in Q4 2018 and held it in 9 quarters. The position peaked at $1.45M in Q2 2020. 49 funds tracked by Wall St. Rank hold SBBP as of Q3 2021.

Boothbay Fund Management reported no remaining Strongbridge Biopharma plc. position as of Q3 2021 after selling out during the quarter.
Boothbay Fund Management sold 143,577 Strongbridge Biopharma plc. shares in Q3 2021, an estimated $426K.
Boothbay Fund Management first reported a position in Strongbridge Biopharma plc. in Q4 2018 and held it in 9 quarters.
Boothbay Fund Management's Strongbridge Biopharma plc. position peaked at $1.45M in Q2 2020.
49 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q3 2021.

Based on Boothbay Fund Management's 13F filing for Q3 2021, filed 15 Nov 2021.